Abstract：
Central retinal vein occlusion and branch retinal vein occlusion are common causes of visual loss due to associated macular oedema. The aim of this review was to assess the effectiveness of interventions improving vision and treating macular oedema in central retinal vein occlusion and branch retinal vein occlusion.
Medical search engines and clinical trial registries were systematically searched. Randomised clinical trials with ≥90 eyes and real-world outcome studies with ≥100 eyes each with ≥6 months follow-up were included.
There were 11 randomised controlled trials evaluating treatments for central retinal vein occlusion which met the inclusion criteria and 10 for branch retinal vein occlusion. There were 10 real world outcome studies of central retinal vein occlusion and 5 real world outcome studies of branch retinal vein occlusion. Meta-analysis was performed on studies that met the defined inclusion criteria. Main outcomes were change in visual acuity at 6-, 12-, 24- and 36 months by treatment.
Intravitreal anti-vascular endothelial derived growth factor is recommended as first line treatment over intravitreal corticosteroid due to its effectiveness and lower rate of ocular adverse events. Best outcomes are achieved when intravitreal treatment is started early. Macular laser may have an adjunctive role in branch retina vein occlusion but not central retinal vein occlusion.
Medical search engines and clinical trial registries were systematically searched. Randomised clinical trials with ≥90 eyes and real-world outcome studies with ≥100 eyes each with ≥6 months follow-up were included.
There were 11 randomised controlled trials evaluating treatments for central retinal vein occlusion which met the inclusion criteria and 10 for branch retinal vein occlusion. There were 10 real world outcome studies of central retinal vein occlusion and 5 real world outcome studies of branch retinal vein occlusion. Meta-analysis was performed on studies that met the defined inclusion criteria. Main outcomes were change in visual acuity at 6-, 12-, 24- and 36 months by treatment.
Intravitreal anti-vascular endothelial derived growth factor is recommended as first line treatment over intravitreal corticosteroid due to its effectiveness and lower rate of ocular adverse events. Best outcomes are achieved when intravitreal treatment is started early. Macular laser may have an adjunctive role in branch retina vein occlusion but not central retinal vein occlusion.
摘要：
背景：视网膜中央静脉阻塞和视网膜分支静脉阻塞是相关黄斑水肿导致视力丧失的常见原因。这篇综述的目的是评估在视网膜中央静脉阻塞和视网膜分支静脉阻塞中改善视力和治疗黄斑水肿的干预措施的有效性。
方法：系统搜索医学搜索引擎和临床试验注册中心。包括≥90只眼的随机临床试验和≥100只眼的真实世界结局研究，每次随访≥6个月。
结果：有11项随机对照试验评估了符合纳入标准的视网膜中央静脉阻塞的治疗方法和10项视网膜分支静脉阻塞的治疗方法。有10个视网膜中央静脉阻塞的真实世界结果研究和5个视网膜分支静脉阻塞的真实世界结果研究。对符合定义的纳入标准的研究进行Meta分析。主要结果是6-，12-，24个月和36个月的治疗。
结论：由于其有效性和较低的眼部不良事件发生率，建议玻璃体内注射抗血管内皮衍生生长因子作为一线治疗优于玻璃体内皮质类固醇。当早期开始玻璃体内治疗时获得最佳结果。黄斑激光可能在视网膜分支静脉阻塞而不是视网膜中央静脉阻塞中起辅助作用。
方法：系统搜索医学搜索引擎和临床试验注册中心。包括≥90只眼的随机临床试验和≥100只眼的真实世界结局研究，每次随访≥6个月。
结果：有11项随机对照试验评估了符合纳入标准的视网膜中央静脉阻塞的治疗方法和10项视网膜分支静脉阻塞的治疗方法。有10个视网膜中央静脉阻塞的真实世界结果研究和5个视网膜分支静脉阻塞的真实世界结果研究。对符合定义的纳入标准的研究进行Meta分析。主要结果是6-，12-，24个月和36个月的治疗。
结论：由于其有效性和较低的眼部不良事件发生率，建议玻璃体内注射抗血管内皮衍生生长因子作为一线治疗优于玻璃体内皮质类固醇。当早期开始玻璃体内治疗时获得最佳结果。黄斑激光可能在视网膜分支静脉阻塞而不是视网膜中央静脉阻塞中起辅助作用。
